BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 27889574)

  • 1. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.
    Dellon ES; Katzka DA; Collins MH; Hamdani M; Gupta SK; Hirano I;
    Gastroenterology; 2017 Mar; 152(4):776-786.e5. PubMed ID: 27889574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results: Analyses From a 12-Week, Phase 2, Randomized, Placebo-controlled Trial.
    Collins MH; Dellon ES; Katzka DA; Hirano I; Williams J; Lan L
    Am J Surg Pathol; 2019 Nov; 43(11):1501-1509. PubMed ID: 31498177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.
    Dellon ES; Woosley JT; Arrington A; McGee SJ; Covington J; Moist SE; Gebhart JH; Tylicki AE; Shoyoye SO; Martin CF; Galanko JA; Baron JA; Shaheen NJ
    Gastroenterology; 2019 Jul; 157(1):65-73.e5. PubMed ID: 30872104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis.
    Dellon ES; Katzka DA; Collins MH; Gupta SK; Lan L; Williams J; Hirano I
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):666-673.e8. PubMed ID: 29902649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial.
    Hirano I; Collins MH; Katzka DA; Mukkada VA; Falk GW; Morey R; Desai NK; Lan L; Williams J; Dellon ES;
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):525-534.e10. PubMed ID: 33887475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis.
    Mukkada VA; Gupta SK; Gold BD; Dellon ES; Collins MH; Katzka DA; Falk GW; Williams J; Zhang W; Boules M; Hirano I; Desai NK
    J Pediatr Gastroenterol Nutr; 2023 Dec; 77(6):760-768. PubMed ID: 37718471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
    Lucendo AJ; Miehlke S; Schlag C; Vieth M; von Arnim U; Molina-Infante J; Hartmann D; Bredenoord AJ; Ciriza de Los Rios C; Schubert S; Brückner S; Madisch A; Hayat J; Tack J; Attwood S; Mueller R; Greinwald R; Schoepfer A; Straumann A;
    Gastroenterology; 2019 Jul; 157(1):74-86.e15. PubMed ID: 30922997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension.
    Dellon ES; Collins MH; Katzka DA; Hudgens S; Lan L; Williams J; Vera-Llonch M; Hirano I
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):699-706.e4. PubMed ID: 32272243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis.
    Gupta SK; Vitanza JM; Collins MH
    Clin Gastroenterol Hepatol; 2015 Jan; 13(1):66-76.e3. PubMed ID: 24907502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
    Dohil R; Newbury R; Fox L; Bastian J; Aceves S
    Gastroenterology; 2010 Aug; 139(2):418-29. PubMed ID: 20457157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis.
    Straumann A; Conus S; Degen L; Frei C; Bussmann C; Beglinger C; Schoepfer A; Simon HU
    Clin Gastroenterol Hepatol; 2011 May; 9(5):400-9.e1. PubMed ID: 21277394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Swallowed Fluticasone Propionate Is an Effective Long-Term Maintenance Therapy for Children With Eosinophilic Esophagitis.
    Andreae DA; Hanna MG; Magid MS; Malerba S; Andreae MH; Bagiella E; Chehade M
    Am J Gastroenterol; 2016 Aug; 111(8):1187-97. PubMed ID: 27325220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective Comparison of Fluticasone Propionate and Oral Viscous Budesonide in Children With Eosinophilic Esophagitis.
    Fable JM; Fernandez M; Goodine S; Lerer T; Sayej WN
    J Pediatr Gastroenterol Nutr; 2018 Jan; 66(1):26-32. PubMed ID: 28489670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis.
    Miehlke S; Hruz P; Vieth M; Bussmann C; von Arnim U; Bajbouj M; Schlag C; Madisch A; Fibbe C; Wittenburg H; Allescher HD; Reinshagen M; Schubert S; Tack J; Müller M; Krummenerl P; Arts J; Mueller R; Dilger K; Greinwald R; Straumann A
    Gut; 2016 Mar; 65(3):390-9. PubMed ID: 25792708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
    Hirano I; Dellon ES; Hamilton JD; Collins MH; Peterson K; Chehade M; Schoepfer AM; Safroneeva E; Rothenberg ME; Falk GW; Assouline-Dayan Y; Zhao Q; Chen Z; Swanson BN; Pirozzi G; Mannent L; Graham NMH; Akinlade B; Stahl N; Yancopoulos GD; Radin A
    Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of Fluticasone to Budesonide in the Treatment of Eosinophilic Esophagitis.
    Albert D; Heifert TA; Min SB; Maydonovitch CL; Baker TP; Chen YJ; Moawad FJ
    Dig Dis Sci; 2016 Jul; 61(7):1996-2001. PubMed ID: 27093866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension.
    Dellon ES; Collins MH; Katzka DA; Mukkada VA; Falk GW; Morey R; Goodwin B; Eisner JD; Lan L; Desai NK; Williams J; Hirano I;
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1488-1498.e11. PubMed ID: 34182150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
    Hirano I; Collins MH; Assouline-Dayan Y; Evans L; Gupta S; Schoepfer AM; Straumann A; Safroneeva E; Grimm M; Smith H; Tompkins CA; Woo A; Peach R; Frohna P; Gujrathi S; Penenberg DN; Li C; Opiteck GJ; Olson A; Aranda R; Rothenberg ME; Dellon ES;
    Gastroenterology; 2019 Feb; 156(3):592-603.e10. PubMed ID: 30395812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 2 delivery vehicles for viscous budesonide to treat eosinophilic esophagitis in children.
    Rubinstein E; Lee JJ; Fried A; Logvinenko T; Ngo P; McDonald D; Hait EJ
    J Pediatr Gastroenterol Nutr; 2014 Sep; 59(3):317-20. PubMed ID: 24821535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Every-other-day Dosing of Oral Viscous Budesonide Is not Effective in the Management of Eosinophlic Esophagitis.
    Rubinstein E; Hait EE; Mitchell PD; Lee JJ
    J Pediatr Gastroenterol Nutr; 2018 Mar; 66(3):395-397. PubMed ID: 28837508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.